Previous 10 | Next 10 |
Biogen ( BIIB ) is a biotechnology company founded by several notable scientists, two Nobel Prize recipients and one knighted. Biogen gained prominence during the late 90's for FDA and European approval of the interferon Avonex for the treatment of relapsing forms of multiple sclerosis (MS'), ...
When United Therapeutics (UTHR) signed a deal with MannKind ( MNKD ) for a dry powder inhaled form of Treprostinil, the company also contracted an undisclosed compound within the PAH space. With United's most recent update of its pipeline page, it appears that the undisclosed compound is Adcir...
SAN DIEGO , March 8, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of ...
Passionate MannKind ( MNKD ) retail investors often contemplate big time buyouts by big pharma, market caps that approach $10 billion, and a situation where the stock goes up to levels which create millionaires. Not a week goes by where there is not some comment about a buyout from Amgen (AMGN...
Arena Pharmaceuticals ( ARNA ) has an estimated $1.3 billion in cash, a billion-dollar licensing deal in the books, and a potential best in class pipeline drug entering phase 3 clinical trials. Simply stated, the company is well positioned, has leverage, and is poised to make some noise in 2...
MannKind ( MNKD ) investors got a little bit of insight regarding its PAH drug candidate TrepT (Dryvaso) from United Therapeutics ( UTHR ) on its Q4 conference call held Wednesday morning. The most important nuggets of information from United Therapeutics which relate to MannKind can be foun...
Arena Pharmaceuticals, Inc. (ARNA) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Kevin Lind - Chief Financial Officer Amit Munshi - President & Chief Executive Officer Conference Call Participants Joseph Schwartz - SVB Leerink Joel B...
Arena Pharmaceuticals (NASDAQ: ARNA ): Q4 EPS of $1.35 may not be comparable to consensus of -$0.77. Revenue of $8.7M (-43.5% Y/Y) beats by $5.37M . Press Release More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
SAN DIEGO , Feb. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2018 . "In 2018 we delivered the steps necessary to position Arena for lo...
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday,...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...